4 unknown. 2 Not applicable, 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Unknown 2 |
| Phase 2 | 2 | Unknown 2 |
| Phase 3 | 1 | Unknown 1 |
Follow Dong Wang: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CIETAI and Sequential Radiotherapy in Squamous Lung Cancer bronchial artery interventional therapy, Chemotherapy drug, IMRT - Carcinoma, Non-Small-Cell Lung | Phase 2 | Unknown | Dong Wang | 50 | 2023-07-01 | 2023-08-23 |
| TC Plus PD-1 Inhibitors Combined With Anlotinib for Advanced Advanced Esophageal Cancer TC/PD-1 inhibitor/anlotinib - ESCC | Not applicable | Unknown | Dong Wang | 90 | 2020-09-01 | 2020-07-15 |
| Endostar/PD-1 Inhibitors Combined With PP for Advanced NSCLC endostar/PD-1 inhibitor, endostar - Non-squamous Non-small Cell Lung Cancer | Not applicable | Unknown | Dong Wang | 170 | 2019-08-20 | 2019-08-21 |
| Paclitaxel (Albumin-bound) and Oxaliplatin for Advanced Hepatobiliary and Malignant Tumors albumin-bound paclitaxel + oxaliplatin - Advanced Hepatobiliary and Malignant Tumors | Phase 2 / Phase 3 | Unknown | Dong Wang | 57 | 2019-08-20 | 2019-08-19 |
Carcinoma, Non-Small-Cell Lung (1) · Neoplasms (1)
Albumin-Bound Paclitaxel (1) · Immunotherapy (1) · Oxaliplatin (1) · anlotinib (1) · endostar protein (1)
China (3)